Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.

Bruin G, Hasselberg A, Koroleva I, Milojevic J, Calonder C, Soon R, Woessner R, Pariser DM, Boutouyrie-Dumont B.

Clin Pharmacol Ther. 2019 Jun 22. doi: 10.1002/cpt.1558. [Epub ahead of print]

PMID:
31228872
2.

Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis.

Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, Porter B, Safi J Jr, Shete A, Bruin G.

J Rheumatol. 2019 Jun 15. pii: jrheum.190116. doi: 10.3899/jrheum.190116. [Epub ahead of print]

PMID:
31203228
3.

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.

Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G.

J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1733-1741. doi: 10.1111/jdv.15637. Epub 2019 Jun 20.

PMID:
31009130
4.

Sleep disturbances are common in patients with autoimmune encephalitis.

Blattner MS, de Bruin GS, Bucelli RC, Day GS.

J Neurol. 2019 Apr;266(4):1007-1015. doi: 10.1007/s00415-019-09230-2. Epub 2019 Feb 11.

PMID:
30741377
5.

Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits.

Xin BT, Huber EM, de Bruin G, Heinemeyer W, Maurits E, Espinal C, Du Y, Janssens M, Weyburne ES, Kisselev AF, Florea BI, Driessen C, van der Marel GA, Groll M, Overkleeft HS.

J Med Chem. 2019 Feb 14;62(3):1626-1642. doi: 10.1021/acs.jmedchem.8b01884. Epub 2019 Feb 5.

6.

Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.

Besse A, Besse L, Kraus M, Mendez-Lopez M, Bader J, Xin BT, de Bruin G, Maurits E, Overkleeft HS, Driessen C.

Cell Chem Biol. 2019 Mar 21;26(3):340-351.e3. doi: 10.1016/j.chembiol.2018.11.007. Epub 2019 Jan 3.

PMID:
30612952
7.

Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.

Basler M, Maurits E, de Bruin G, Koerner J, Overkleeft HS, Groettrup M.

Br J Pharmacol. 2018 Jan;175(1):38-52. doi: 10.1111/bph.14069. Epub 2017 Nov 29.

8.

Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification.

Widjaja CE, Olvera JG, Metz PJ, Phan AT, Savas JN, de Bruin G, Leestemaker Y, Berkers CR, de Jong A, Florea BI, Fisch K, Lopez J, Kim SH, Garcia DA, Searles S, Bui JD, Chang AN, Yates JR 3rd, Goldrath AW, Overkleeft HS, Ovaa H, Chang JT.

J Clin Invest. 2017 Oct 2;127(10):3609-3623. doi: 10.1172/JCI90895. Epub 2017 Aug 28.

9.

Monitoring the Diagnostic Process on an Inpatient Neurology Service.

Dhand A, Bucelli R, Varadhachary A, Tsiaklides M, de Bruin G, Dhaliwal G.

Neurohospitalist. 2017 Jul;7(3):132-136. doi: 10.1177/1941874416677681. Epub 2016 Nov 16.

10.

Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.

Bruin G, Loesche C, Nyirady J, Sander O.

J Clin Pharmacol. 2017 Jul;57(7):876-885. doi: 10.1002/jcph.876. Epub 2017 Mar 8.

11.

Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.

Weyburne ES, Wilkins OM, Sha Z, Williams DA, Pletnev AA, de Bruin G, Overkleeft HS, Goldberg AL, Cole MD, Kisselev AF.

Cell Chem Biol. 2017 Feb 16;24(2):218-230. doi: 10.1016/j.chembiol.2016.12.016. Epub 2017 Jan 26.

12.

A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit β5i.

Huber EM, Heinemeyer W, de Bruin G, Overkleeft HS, Groll M.

EMBO J. 2016 Dec 1;35(23):2602-2613. Epub 2016 Oct 27.

13.

The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies.

Bhattarai S, Ghannam K, Krause S, Benveniste O, Marg A, de Bruin G, Xin BT, Overkleeft HS, Spuler S, Stenzel W, Feist E.

J Autoimmun. 2016 Dec;75:118-129. doi: 10.1016/j.jaut.2016.08.004. Epub 2016 Aug 10.

PMID:
27522114
14.

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.

Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, Papavassilis C, Liang E, Lloyd P, Bruin G.

Br J Dermatol. 2017 Mar;176(3):752-758. doi: 10.1111/bjd.14965. Epub 2016 Nov 22.

PMID:
27518376
15.

β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.

Kolbinger F, Loesche C, Valentin MA, Jiang X, Cheng Y, Jarvis P, Peters T, Calonder C, Bruin G, Polus F, Aigner B, Lee DM, Bodenlenz M, Sinner F, Pieber TR, Patel DD.

J Allergy Clin Immunol. 2017 Mar;139(3):923-932.e8. doi: 10.1016/j.jaci.2016.06.038. Epub 2016 Aug 5.

16.

Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes.

Xin BT, de Bruin G, Huber EM, Besse A, Florea BI, Filippov DV, van der Marel GA, Kisselev AF, van der Stelt M, Driessen C, Groll M, Overkleeft HS.

J Med Chem. 2016 Aug 11;59(15):7177-87. doi: 10.1021/acs.jmedchem.6b00705. Epub 2016 Aug 1.

PMID:
27438186
17.

Proteasome Subunit Selective Activity-Based Probes Report on Proteasome Core Particle Composition in a Native Polyacrylamide Gel Electrophoresis Fluorescence-Resonance Energy Transfer Assay.

de Bruin G, Xin BT, Florea BI, Overkleeft HS.

J Am Chem Soc. 2016 Aug 10;138(31):9874-80. doi: 10.1021/jacs.6b04207. Epub 2016 Jul 26.

PMID:
27428761
18.

Sleep Pathology in Creutzfeldt-Jakob Disease.

Kang P, de Bruin GS, Wang LH, Ward BA, Ances BM, Lim MM, Bucelli RC.

J Clin Sleep Med. 2016 Jul 15;12(7):1033-9. doi: 10.5664/jcsm.5944.

19.

Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197.

De Buck S, Hueber W, Vitaliti A, Straube F, Emotte C, Bruin G, Woessner R.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):691-700. doi: 10.1002/psp4.12037. Epub 2015 Nov 9.

20.

Enantioselective synthesis of adamantylalanine and carboranylalanine and their incorporation into the proteasome inhibitor bortezomib.

de Bruin G, Mock ED, Hoogendoorn S, van den Nieuwendijk AM, Mazurek J, van der Marel GA, Florea BI, Overkleeft HS.

Chem Commun (Camb). 2016 Mar 14;52(21):4064-7. doi: 10.1039/c6cc01156j.

PMID:
26894389
21.

A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities.

de Bruin G, Xin BT, Kraus M, van der Stelt M, van der Marel GA, Kisselev AF, Driessen C, Florea BI, Overkleeft HS.

Angew Chem Int Ed Engl. 2016 Mar 18;55(13):4199-203. doi: 10.1002/anie.201509092. Epub 2015 Oct 29.

PMID:
26511210
22.

Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion.

Dragatin C, Polus F, Bodenlenz M, Calonder C, Aigner B, Tiffner KI, Mader JK, Ratzer M, Woessner R, Pieber TR, Cheng Y, Loesche C, Sinner F, Bruin G.

Exp Dermatol. 2016 Feb;25(2):157-9. doi: 10.1111/exd.12863. Epub 2015 Nov 23. No abstract available.

PMID:
26439798
23.

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C.

Cancer Chemother Pharmacol. 2015 Aug;76(2):383-96. doi: 10.1007/s00280-015-2801-0. Epub 2015 Jun 23.

24.

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.

Kraus M, Bader J, Geurink PP, Weyburne ES, Mirabella AC, Silzle T, Shabaneh TB, van der Linden WA, de Bruin G, Haile SR, van Rooden E, Appenzeller C, Li N, Kisselev AF, Overkleeft H, Driessen C.

Haematologica. 2015 Oct;100(10):1350-60. doi: 10.3324/haematol.2014.109421. Epub 2015 Jun 11.

25.

Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.

Huber EM, de Bruin G, Heinemeyer W, Paniagua Soriano G, Overkleeft HS, Groll M.

J Am Chem Soc. 2015 Jun 24;137(24):7835-42. doi: 10.1021/jacs.5b03688. Epub 2015 Jun 11.

PMID:
26020686
26.

Reply: To PMID 25141833.

Bruin G.

Can J Anaesth. 2015 Apr;62(4):425-6. No abstract available.

PMID:
25884069
27.

Bifactor analysis of the mental health continuum-short form (MHC-SF).

de Bruin GP, du Plessis GA.

Psychol Rep. 2015 Apr;116(2):438-46. doi: 10.2466/03.02.PR0.116k20w6. Epub 2015 Mar 2.

PMID:
25730745
28.

Childhood cancer survival rates in two South African units.

Stones DK, De Bruin GP, Esterhuizen TM, Stefan DC.

S Afr Med J. 2014 May 19;104(7):501-4. doi: 10.7196/samj.7882.

PMID:
25214053
29.

Lung re-inflation after one-lung ventilation for thoracic surgery: importance of clamping the dependent lung.

Bruin G.

Can J Anaesth. 2014 Nov;61(11):1061. doi: 10.1007/s12630-014-0222-x. Epub 2014 Aug 21. No abstract available.

PMID:
25141833
30.

Proteasome inhibitors with photocontrolled activity.

Hansen MJ, Velema WA, de Bruin G, Overkleeft HS, Szymanski W, Feringa BL.

Chembiochem. 2014 Sep 22;15(14):2053-7. doi: 10.1002/cbic.201402237. Epub 2014 Aug 14.

PMID:
25125335
31.

Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.

de Bruin G, Huber EM, Xin BT, van Rooden EJ, Al-Ayed K, Kim KB, Kisselev AF, Driessen C, van der Stelt M, van der Marel GA, Groll M, Overkleeft HS.

J Med Chem. 2014 Jul 24;57(14):6197-209. doi: 10.1021/jm500716s. Epub 2014 Jul 15.

PMID:
25006746
32.

Exploring dual electrophiles in peptide-based proteasome inhibitors: carbonyls and epoxides.

Xin BT, de Bruin G, Verdoes M, Filippov DV, van der Marel GA, Overkleeft HS.

Org Biomol Chem. 2014 Aug 14;12(30):5710-8. doi: 10.1039/c4ob00893f. Epub 2014 Jun 26.

PMID:
24968066
33.

AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women.

John MR, Harfst E, Loeffler J, Belleli R, Mason J, Bruin GJ, Seuwen K, Klickstein LB, Mindeholm L, Widler L, Kneissel M.

Bone. 2014 Jul;64:204-10. doi: 10.1016/j.bone.2014.04.015. Epub 2014 Apr 24.

PMID:
24769332
34.

Toward understanding induction of oxidative stress and apoptosis by proteasome inhibitors.

Paniagua Soriano G, De Bruin G, Overkleeft HS, Florea BI.

Antioxid Redox Signal. 2014 Dec 10;21(17):2419-43. doi: 10.1089/ars.2013.5794. Epub 2014 Mar 4. Review.

PMID:
24437477
35.

Children with kaposi sarcoma in two southern african hospitals: clinical presentation, management, and outcome.

De Bruin GP, Stefan DC.

J Trop Med. 2013;2013:213490. doi: 10.1155/2013/213490. Epub 2013 Dec 11.

36.

A combined solid- and solution-phase approach provides convenient access to analogues of the calcium-dependent lipopeptide antibiotics.

't Hart P, Kleijn LH, de Bruin G, Oppedijk SF, Kemmink J, Martin NI.

Org Biomol Chem. 2014 Feb 14;12(6):913-8. doi: 10.1039/c3ob42238k.

PMID:
24346297
37.

Dimensionality of the 9-item Utrecht Work Engagement Scale (UWES-9).

de Bruin GP, Henn CM.

Psychol Rep. 2013 Jun;112(3):788-99.

PMID:
24245073
38.

Nanoparticle flotation collectors--the influence of particle softness.

Yang S, Razavizadeh BB, Pelton R, Bruin G.

ACS Appl Mater Interfaces. 2013 Jun 12;5(11):4836-42. doi: 10.1021/am4008825. Epub 2013 May 31.

PMID:
23692163
39.

Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites.

Geurink PP, van der Linden WA, Mirabella AC, Gallastegui N, de Bruin G, Blom AE, Voges MJ, Mock ED, Florea BI, van der Marel GA, Driessen C, van der Stelt M, Groll M, Overkleeft HS, Kisselev AF.

J Med Chem. 2013 Feb 14;56(3):1262-75. doi: 10.1021/jm3016987. Epub 2013 Jan 28.

40.

The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers.

Kirsten A, Watz H, Pedersen F, Holz O, Smith R, Bruin G, Koehne-Voss S, Magnussen H, Waltz DA.

Eur Respir J. 2013 Jan;41(1):239-41. doi: 10.1183/09031936.00123612. No abstract available.

41.

Oscillation characteristics of endodontic files: numerical model and its validation.

Verhaagen B, Lea SC, de Bruin GJ, van der Sluis LW, Walmsley AD, Versluis M.

IEEE Trans Ultrason Ferroelectr Freq Control. 2012 Nov;59(11):2448-59. doi: 10.1109/TUFFC.2012.2477.

PMID:
23192808
42.

The effect of response style on self-reported Conscientiousness across 20 countries.

Mõttus R, Allik J, Realo A, Rossier J, Zecca G, Ah-Kion J, Amoussou-Yéyé D, Bäckström M, Barkauskiene R, Barry O, Bhowon U, Björklund F, Bochaver A, Bochaver K, de Bruin G, Cabrera HF, Chen SX, Church AT, Cissé DD, Dahourou D, Feng X, Guan Y, Hwang HS, Idris F, Katigbak MS, Kuppens P, Kwiatkowska A, Laurinavicius A, Mastor KA, Matsumoto D, Riemann R, Schug J, Simpson B, Tseung-Wong CN, Johnson W.

Pers Soc Psychol Bull. 2012 Nov;38(11):1423-36. doi: 10.1177/0146167212451275. Epub 2012 Jun 27.

43.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group.

Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17.

44.

Challenges to treatment of leukemia in HIV-positive children.

Stefan DC, Dippenaar A, De Bruin G, Uys R, van Toorn R.

J Trop Pediatr. 2012 Dec;58(6):521-2. doi: 10.1093/tropej/fms007. Epub 2012 Mar 14.

PMID:
22421805
45.

Exploring the personality structure in the 11 languages of South Africa.

Nel JA, Valchev VH, Rothmann S, van de Vijver FJ, Meiring D, de Bruin GP.

J Pers. 2012 Aug;80(4):915-48. doi: 10.1111/j.1467-6494.2011.00751.x. Epub 2012 Jun 29.

PMID:
22091948
46.

Stroke complicating traumatic ventricular septal defect.

de Bruin G, Pereira da Silva R.

J Emerg Med. 2012 Dec;43(6):987-8. doi: 10.1016/j.jemermed.2011.03.013. Epub 2011 May 26.

PMID:
21620609
47.

ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans.

John MR, Widler L, Gamse R, Buhl T, Seuwen K, Breitenstein W, Bruin GJ, Belleli R, Klickstein LB, Kneissel M.

Bone. 2011 Aug;49(2):233-41. doi: 10.1016/j.bone.2011.04.007. Epub 2011 Apr 14.

PMID:
21514409
48.

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.

Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH; Psoriasis Study Group, Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group, Rose K, Haider A, Di Padova F.

Sci Transl Med. 2010 Oct 6;2(52):52ra72. doi: 10.1126/scitranslmed.3001107.

49.

Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.

Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, Porter JB.

Drug Metab Dispos. 2010 May;38(5):808-16. doi: 10.1124/dmd.109.030833. Epub 2010 Jan 22.

PMID:
20097723
50.

[Ogilvie Syndrome induced by clozapine].

de Bruin GJ, Bac DJ, van Puijenbroek EP, van der Klooster JM.

Ned Tijdschr Geneeskd. 2009;153:B437. Dutch.

PMID:
20051163

Supplemental Content

Support Center